Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Lewis SJ, Caldwell MA, Barker RA. Modern therapeutic approaches in Parkinson's disease. Expert Rev. Mol. Med. 5(10), 1–20 (2003).
  MedlineGoogle Scholar
• 2 Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448–458 (2001).
  Medline CASGoogle Scholar
• 3 Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20(Suppl. 11), S11–S16 (2005).
  MedlineGoogle Scholar
• 4 Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch. Neurol. 63(2), 205–209 (2006).
  MedlineGoogle Scholar
• 5 Schumacher-Schuh AF, Rieder CR, Hutz MH. Parkinson's disease pharmacogenomics: new findings and perspectives. Pharmacogenomics 15(9), 1253–1271 (2014).•• This is a systematic review of the literature on Parkinson's disease (PD) pharmacogenetics to provide a critical discussion of the existent findings, new approach limitations and recommendations for future research. It focuses on the number of studies, which continues to grow, and the heterogeneity in methodological strategies employed by different studies.
  CASGoogle Scholar
• 6 Armentero MT, Pinna A, Ferre S, Lanciego JL, Muller CE, Franco R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther. 132(3), 280–299 (2011).• Overview of A2A receptor (A2AR) antagonists’ role in PD.
  Medline CASGoogle Scholar
• 7 Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol. 83(5), 293–309 (2007).
  Medline CASGoogle Scholar
• 8 Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S. Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol. 83(5), 277–292 (2007).
  Medline CASGoogle Scholar
• 9 Rieck M, Schumacher-Schuh AF, Altmann V et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 13(15), 1701–1710 (2012).
  CASGoogle Scholar
• 10 Schumacher-Schuh AF, Altmann V, Rieck M et al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. Pharmacogenomics J. 14(3), 289–294 (2014).
  Medline CASGoogle Scholar
• 11 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55(3), 181–184 (1992).
  Medline CASGoogle Scholar
• 12 Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov. Disord. 9(1), 76–83 (1994).
  Medline CASGoogle Scholar
• 13 Long J. Multiple Locus Haplotype Analysis, version 3.0: software and documentation distributed by the author. Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA, 4819–0618 (1999).
  Google Scholar
• 14 Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68(4), 978–989 (2001).
  Medline CASGoogle Scholar
• 15 Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76(3), 449–462 (2005).
  Medline CASGoogle Scholar
• 16 Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case–control studies. Am. J. Epidemiol. 160(4), 301–305 (2004).
  MedlineGoogle Scholar
• 17 Yu L, Frith MC, Suzuki Y et al. Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses. Brain Res. 1000(1–2), 156–173 (2004).
  Medline CASGoogle Scholar
• 18 Conde L, Vaquerizas JM, Dopazo H et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res. 34(Web Server issue), W621–W625 (2006).
  Medline CASGoogle Scholar
• 19 Guntaka RV, Varma BR, Weber KT. Triplex-forming oligonucleotides as modulators of gene expression. Int. J. Biochem. Cell Biol. 35(1), 22–31 (2003).
  Medline CASGoogle Scholar
• 20 Besch R, Giovannangeli C, Degitz K. Triplex-forming oligonucleotides – sequence-specific DNA ligands as tools for gene inhibition and for modulation of DNA-associated functions. Curr. Drug Targets 5(8), 691–703 (2004).
  Medline CASGoogle Scholar
• 21 Goni JR, De La Cruz X, Orozco M. Triplex-forming oligonucleotide target sequences in the human genome. Nucleic Acids Res. 32(1), 354–360 (2004).
  Medline CASGoogle Scholar
• 22 Ivanova SA, Loonen AJ, Pechlivanoglou P et al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl. Psychiatry 2, e67 (2012).
  Medline CASGoogle Scholar
• 23 Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 18(1), 15–20 (2013).
  MedlineGoogle Scholar
• 24 Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov. Disord. 28(2), 131–144 (2013).• Review of A2AR antagonists targets in development for PD therapy.
  Medline CASGoogle Scholar
• 25 Kanda T, Jackson MJ, Smith LA et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43(4), 507–513 (1998).
  Medline CASGoogle Scholar
• 26 Bibbiani F, Oh JD, Petzer JP et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184(1), 285–294 (2003).
  Medline CASGoogle Scholar
• 27 Wei CJ, Li W, Chen JF. Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim. Biophys. Acta 1808(5), 1358–1379 (2011).
  Medline CASGoogle Scholar
• 28 Kulisevsky J, Poyurovsky M. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders. Eur. Neurol. 67(1), 4–11 (2012).•• Review of A2AR role in the pathophysiology of PD and drug-induced movement disorders.
  Medline CASGoogle Scholar
• 29 Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson's disease: what's next? Curr. Neurol. Neurosci. Rep. 12(4), 376–385 (2012).
  Medline CASGoogle Scholar
• 30 Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol. Rev. 65(1), 171–222 (2013).
  Medline CASGoogle Scholar
• 31 Pollack AE, Fink JS. Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68(3), 721–728 (1995).
  Medline CASGoogle Scholar
• 32 Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 100(1), 53–62 (2000).
  Medline CASGoogle Scholar
• 33 Ochi M, Shiozaki S, Kase H. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience 127(1), 223–231 (2004).
  Medline CASGoogle Scholar
• 34 Fuxe K, Ferre S, Genedani S, Franco R, Agnati LF. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol. Behav. 92(1–2), 210–217 (2007).•• Review of A2AR–DRD2 interaction highlights its importance for brain function.
  Medline CASGoogle Scholar
• 35 Tozzi A, Tscherter A, Belcastro V et al. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 53(6), 783–789 (2007).
  Medline CASGoogle Scholar
• 36 Tozzi A, De Iure A, Di Filippo M et al. The distinct role of medium spiny neurons and cholinergic interneurons in the D(2)/A(2)A receptor interaction in the striatum: implications for Parkinson's disease. J. Neurosci. 31(5), 1850–1862 (2011).
  Medline CASGoogle Scholar
• 37 Varani K, Vincenzi F, Tosi A et al. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J. 24(2), 587–598 (2010).
  Medline CASGoogle Scholar
• 38 Casetta I, Vincenzi F, Bencivelli D et al. A(2A) adenosine receptors and Parkinson's disease severity. Acta Neurol. Scand. 129(4), 276–281 (2014).
  Medline CASGoogle Scholar
• 39 Villar-Menendez I, Porta S, Buira SP et al. Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b. Neurobiol. Dis. 69, 206–214 (2014).
  Medline CASGoogle Scholar
• 40 Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127(Pt 5), 1075–1084 (2004).
  MedlineGoogle Scholar
• 41 Mishina M, Ishiwata K, Naganawa M et al. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS ONE 6(2), e17338 (2011).
  Medline CASGoogle Scholar
• 42 Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76(21), 1811–1816 (2011).
  Medline CASGoogle Scholar
• 43 Chen JF, Sonsalla PK, Pedata F et al. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and ‘fine tuning’ modulation. Prog. Neurobiol. 83(5), 310–331 (2007).
  Medline CASGoogle Scholar
• 44 Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets – what are the challenges? Nat. Rev. Drug Discov. 12(4), 265–286 (2013).
  Medline CASGoogle Scholar
• 45 Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J. Immunol. 167(7), 4026–4032 (2001).
  Medline CASGoogle Scholar
• 46 Kermanian F, Soleimani M, Ebrahimzadeh A, Haghir H, Mehdizadeh M. Effects of adenosine A2a receptor agonist and antagonist on hippocampal nuclear factor-kB expression preceded by MDMA toxicity. Metab. Brain Dis. 28(1), 45–52 (2013).
  Medline CASGoogle Scholar
• 47 Bontempi S, Fiorentini C, Busi C, Guerra N, Spano P, Missale C. Identification and characterization of two nuclear factor-kappaB sites in the regulatory region of the dopamine D2 receptor. Endocrinology 148(5), 2563–2570 (2007).
  Medline CASGoogle Scholar
• 48 Childs E, Hohoff C, Deckert J, Xu K, Badner J, De Wit H. Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 33(12), 2791–2800 (2008).
  Medline CASGoogle Scholar
• 49 Freitag CM, Agelopoulos K, Huy E et al. Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder. Eur Child Adolesc Psychiatry 19(1), 67–74 (2010).
  MedlineGoogle Scholar
• 50 Hohoff C, Mullings EL, Heatherley SV et al. Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality. J. Psychiatr Res. 44(14), 930–937 (2010).
  MedlineGoogle Scholar
• 51 Jagannathan K, Calhoun VD, Gelernter J et al. Genetic associations of brain structural networks in schizophrenia: a preliminary study. Biol. Psychiatry 68(7), 657–666 (2010).
  Medline CASGoogle Scholar
• 52 Rogers PJ, Hohoff C, Heatherley SV et al. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 35(9), 1973–1983 (2010).
  Medline CASGoogle Scholar
• 53 Beste C, Stock AK, Ness V, Epplen JT, Arning L. Differential effects of ADORA2A gene variations in preattentive visual sensory memory subprocesses. Eur. Neuropsychopharmacol. 22(8), 555–561 (2012).
  Medline CASGoogle Scholar
• 54 Popat RA, Van Den Eeden SK, Tanner CM et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur. J. Neurol. 18(5), 756–765 (2011).•• First study to investigate the genetic link between ADORA2A and PD.
  Medline CASGoogle Scholar
• 55 Greenbaum L, Cohen OS, Inzelberg R et al. Association of the adenosine receptor A2A (ADORA2A) gene with L-dopa induced dyskinesia in Parkinson's disease [abstract]. Mov. Disord. 27(Suppl. 1), 1385 (2012).
  Google Scholar
• 56 Perneger TV. What's wrong with Bonferroni adjustments. BMJ 316(7139), 1236–1238 (1998).
  Medline CASGoogle Scholar
• 57 Colosimo C, Martinez-Martin P, Fabbrini G et al. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov. Disord. 25(9), 1131–1142 (2010).
  MedlineGoogle Scholar